Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 477

1.

Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016).

Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S34-S46. doi: 10.1093/ofid/ofy293. eCollection 2019 Mar.

2.

Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program.

Castanheira M, Deshpande LM, Mendes RE, Canton R, Sader HS, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S23-S33. doi: 10.1093/ofid/ofy347. eCollection 2019 Mar.

3.

Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Sader HS, Mendes RE, Le J, Denys G, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S14-S23. doi: 10.1093/ofid/ofy263. eCollection 2019 Mar.

4.

Antimicrobial Resistance Surveillance and New Drug Development.

Sader HS, Rhomberg PR, Fuhrmeister AS, Mendes RE, Flamm RK, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S5-S13. doi: 10.1093/ofid/ofy345. eCollection 2019 Mar.

6.
7.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE, Sader HS.

Diagn Microbiol Infect Dis. 2019 Jan 26. pii: S0732-8893(18)30625-4. doi: 10.1016/j.diagmicrobio.2019.01.015. [Epub ahead of print]

PMID:
30808530
8.

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.

Sader HS, Mendes RE, Pfaller MA, Flamm RK.

J Antimicrob Chemother. 2019 Feb 7. doi: 10.1093/jac/dkz006. [Epub ahead of print]

PMID:
30753485
9.

In Vitro Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant Staphylococcus aureus (2014-2015) in the United States.

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK, Mendes RE.

Microb Drug Resist. 2019 Jan 29. doi: 10.1089/mdr.2018.0410. [Epub ahead of print]

PMID:
30694735
10.

Low prevalence of Gram-positive isolates showing elevated lefamulin MIC results during the surveillance program for 2015-2016 and characterization of resistance mechanisms.

Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02158-18. doi: 10.1128/AAC.02158-18. [Epub ahead of print]

PMID:
30670418
11.

Antibacterial Activity of Lefamulin Against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02161-18. doi: 10.1128/AAC.02161-18. [Epub ahead of print]

PMID:
30670415
12.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Carvalhaes CG, Castanheira M, Sader HS, Flamm RK, Shortridge D.

Diagn Microbiol Infect Dis. 2018 Nov 30. pii: S0732-8893(18)30425-5. doi: 10.1016/j.diagmicrobio.2018.11.021. [Epub ahead of print]

PMID:
30642717
13.

Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).

Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02262-18. doi: 10.1128/AAC.02262-18. Print 2019 Mar.

PMID:
30617092
14.

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

Duncan LR, Flamm RK, Sader HS, Mendes RE.

Diagn Microbiol Infect Dis. 2019 Feb;93(2):167-170. doi: 10.1016/j.diagmicrobio.2018.09.011. Epub 2018 Oct 2.

15.

Frequency and Antimicrobial Susceptibility of Bacterial Isolates from Patients Hospitalised with Community-Acquired Skin and Skin Structure Infection in Europe, Asia, and Latin America.

Sader HS, Streit JM, Carvalhaes CG, Huband MD, Pfaller MA.

J Glob Antimicrob Resist. 2018 Nov 17. pii: S2213-7165(18)30229-7. doi: 10.1016/j.jgar.2018.11.013. [Epub ahead of print]

PMID:
30458298
16.

Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016.

Pfaller MA, Flamm RK, Mendes RE, Streit JM, Smart JI, Hamed KA, Duncan LR, Sader HS.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01566-18. doi: 10.1128/AAC.01566-18. Print 2019 Jan.

PMID:
30373807
17.

Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.

Sader HS, Flamm RK, Streit JM, Carvalhaes CG, Mendes RE.

Int J Infect Dis. 2018 Dec;77:82-86. doi: 10.1016/j.ijid.2018.10.004. Epub 2018 Oct 10.

18.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam.

Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R.

Infect Drug Resist. 2018 Sep 17;11:1499-1510. doi: 10.2147/IDR.S173804. eCollection 2018.

19.

Evaluation of the Revised Ceftaroline Disk Diffusion Breakpoints When Testing a Challenge Collection of Methicillin-Resistant Staphylococcus aureus Isolates.

Sader HS, Rhomberg PR, Doyle TB, Flamm RK, Mendes RE.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e00777-18. doi: 10.1128/JCM.00777-18. Print 2018 Dec.

20.

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01587-18. doi: 10.1128/AAC.01587-18. Print 2018 Dec.

PMID:
30224535
21.

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17).

Sader HS, Castanheira M, Mendes RE, Flamm RK.

J Antimicrob Chemother. 2018 Nov 1;73(11):3053-3059. doi: 10.1093/jac/dky279.

PMID:
30060117
22.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16.

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

J Antimicrob Chemother. 2018 Oct 1;73(10):2748-2756. doi: 10.1093/jac/dky235.

PMID:
29982565
23.

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.

Sader HS, Flamm RK, Dale GE, Rhomberg PR, Castanheira M.

J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404. doi: 10.1093/jac/dky227.

PMID:
29901750
24.
25.

Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.

Sader HS, Dale GE, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00311-18. doi: 10.1128/AAC.00311-18. Print 2018 Jul.

26.

ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries.

Mendes RE, Deshpande L, Streit JM, Sader HS, Castanheira M, Hogan PA, Flamm RK.

J Antimicrob Chemother. 2018 Jul 1;73(7):1880-1887. doi: 10.1093/jac/dky099.

PMID:
29659858
27.

Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):199-204. doi: 10.1016/j.diagmicrobio.2018.01.029. Epub 2018 Feb 3.

PMID:
29567128
28.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.

Sader HS, Rhomberg PR, Huband MD, Critchley IA, Stone GG, Flamm RK, Jones RN.

J Clin Microbiol. 2018 May 25;56(6). pii: e01960-17. doi: 10.1128/JCM.01960-17. Print 2018 Jun.

29.

Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).

Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS.

Int J Antimicrob Agents. 2018 Jun;51(6):848-853. doi: 10.1016/j.ijantimicag.2018.01.006. Epub 2018 Feb 2.

PMID:
29410368
30.

Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).

Pfaller MA, Flamm RK, Duncan LR, Streit JM, Castanheira M, Sader HS.

Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.

31.

Erratum for Pfaller et al., "In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014".

Pfaller MA, Sader HS, Rhomberg PR, Flamm RK.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02383-17. doi: 10.1128/AAC.02383-17. Print 2018 Feb. No abstract available.

32.

Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16).

Pfaller MA, Sader HS, Castanheira M, Flamm RK, Mendes RE.

J Antimicrob Chemother. 2018 Apr 1;73(4):916-922. doi: 10.1093/jac/dkx485.

PMID:
29294031
33.

Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).

Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE.

Int J Antimicrob Agents. 2018 Apr;51(4):608-611. doi: 10.1016/j.ijantimicag.2017.12.011. Epub 2017 Dec 23.

PMID:
29277526
34.

Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02397-17. doi: 10.1128/AAC.02397-17. Print 2018 Mar.

35.

Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02125-17. doi: 10.1128/AAC.02125-17. Print 2018 Mar.

36.
37.

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).

Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01555-17. doi: 10.1128/AAC.01555-17. Print 2018 Feb.

38.

The application of in vitro surveillance data for antibacterial dose selection.

Flamm RK, Sader HS, Castanheira M, Jones RN.

Curr Opin Pharmacol. 2017 Oct;36:130-138. doi: 10.1016/j.coph.2017.10.009. Epub 2017 Nov 11. Review.

PMID:
29136540
39.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01856-17. doi: 10.1128/AAC.01856-17. Print 2018 Jan.

40.
41.

In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program.

Flamm RK, Rhomberg PR, Sader HS.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01230-17. doi: 10.1128/AAC.01230-17. Print 2017 Dec.

42.

Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride.

Castanheira M, Duncan LR, Rhomberg PR, Sader HS.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):305-309. doi: 10.1016/j.diagmicrobio.2017.08.011. Epub 2017 Aug 24.

PMID:
28969934
43.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Gales A, Castanheira M, Flamm RK.

Braz J Infect Dis. 2017 Nov - Dec;21(6):627-637. doi: 10.1016/j.bjid.2017.06.008. Epub 2017 Sep 21.

44.

Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01045-17. doi: 10.1128/AAC.01045-17. Print 2017 Nov.

45.
46.

Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).

Pfaller MA, Mendes RE, Sader HS, Castanheira M, Flamm RK.

J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.

PMID:
28735053
47.

Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014).

Duncan LR, Sader HS, Smart JI, Flamm RK, Mendes RE.

J Glob Antimicrob Resist. 2017 Sep;10:271-276. doi: 10.1016/j.jgar.2017.03.018. Epub 2017 Jul 19.

PMID:
28735051
48.

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.

J Glob Antimicrob Resist. 2017 Sep;10:186-194. doi: 10.1016/j.jgar.2017.05.025. Epub 2017 Jul 19.

PMID:
28735046
49.

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions.

Pfaller MA, Sader HS, Flamm RK, Castanheira M, Smart JI, Mendes RE.

Microb Drug Resist. 2017 Sep;23(6):718-726. doi: 10.1089/mdr.2017.0022. Epub 2017 Jul 20.

50.

Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.

Sader HS, Mendes RE, Streit JM, Flamm RK.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01043-17. doi: 10.1128/AAC.01043-17. Print 2017 Sep.

Supplemental Content

Loading ...
Support Center